PMID- 35725413 OWN - NLM STAT- MEDLINE DCOM- 20220622 LR - 20220716 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 22 IP - 1 DP - 2022 Jun 20 TI - The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients. PG - 676 LID - 10.1186/s12885-022-09783-y [doi] LID - 676 AB - BACKGROUND: Bladder cancer (BCa) shows its potential immunogenity in current immune-checkpoint inhibitor related immunotherapies. However, its therapeutic effects are improvable and could be affected by tumor immune microenvironment. Hence it is interesting to find some more prognostic indicators for BCa patients concerning immunotherapies. METHODS: In the present study, we retrospect 129 muscle-invasive BCa (MIBC) patients with radical cystectomy in Shanghai General Hospital during 2007 to 2018. Based on the results of proteomics sequencing from 9 pairs of MIBC tissue from Shanghai General Hospital, we focused on 13 immune-related differential expression proteins and their related genes. An immune-related prognostic signature (IRPS) was constructed according to Cancer Genome Atlas (TCGA) dataset. The IRPS was verified in ArrayExpress (E-MTAB-4321) cohort and Shanghai General Hospital (General) cohort, separately. A total of 1010 BCa patients were involved in the study, including 405 BCa patients in TCGA cohort, 476 BCa patients in E-MTAB-4321 cohort and 129 MIBC patients in General cohort. RESULT: It can be indicated that high IRPS score was related to poor 5-year overall survival and disease-free survival. The IRPS score was also evaluated its immune infiltration. We found that the IRPS score was adversely associated with GZMB, IFN-gamma, PD-1, PD-L1. Additionally, higher IRPS score was significantly associated with more M2 macrophage and resting mast cell infiltration. CONCLUSION: The study revealed a novel BCa prognostic signature based on IRPS score, which may be useful for BCa immunotherapies. CI - (c) 2022. The Author(s). FAU - Jiang, Liren AU - Jiang L AD - Pathology Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100, Hai Ning Road, Shanghai, 200080, China. FAU - Chen, Siteng AU - Chen S AD - Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Pan, Qi AU - Pan Q AD - Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Zheng, Jun AU - Zheng J AD - Pathology Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100, Hai Ning Road, Shanghai, 200080, China. FAU - He, Jin AU - He J AD - Pathology Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100, Hai Ning Road, Shanghai, 200080, China. FAU - Sun, Juanjuan AU - Sun J AD - Pathology Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100, Hai Ning Road, Shanghai, 200080, China. FAU - Han, Yaqin AU - Han Y AD - Pathology Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100, Hai Ning Road, Shanghai, 200080, China. FAU - Yang, Jiji AU - Yang J AD - Pathology Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100, Hai Ning Road, Shanghai, 200080, China. FAU - Zhang, Ning AU - Zhang N AD - Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin 2nd Road, Shanghai, 200020, China. zn12235@rjh.com.cn. FAU - Fu, Guohui AU - Fu G AD - Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Institutes of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China. guohuifu@shsmu.edu.cn. AD - Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 280, South Chong-Qing Road, Shanghai, 200025, China. guohuifu@shsmu.edu.cn. FAU - Gao, Feng AU - Gao F AD - Pathology Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100, Hai Ning Road, Shanghai, 200080, China. gaofeng197205@outlook.com. LA - eng GR - No.81902569/National Natural Science Foundation of China/ GR - No.82002665/National Natural Science Foundation of China/ GR - shslczdzk01303/Shanghai Municipal Key Clinical Specialty/ PT - Journal Article DEP - 20220620 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) SB - IM MH - Biomarkers, Tumor/genetics MH - China MH - Feasibility Studies MH - Humans MH - Prognosis MH - Proteomics MH - Tumor Microenvironment MH - *Urinary Bladder Neoplasms/genetics/pathology/therapy PMC - PMC9210750 OTO - NOTNLM OT - Bladder cancer OT - Immune-related OT - PD-1 OT - PD-L1 OT - Prognostic signature COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/06/21 06:00 MHDA- 2022/06/23 06:00 PMCR- 2022/06/20 CRDT- 2022/06/20 23:34 PHST- 2021/11/24 00:00 [received] PHST- 2022/06/15 00:00 [accepted] PHST- 2022/06/20 23:34 [entrez] PHST- 2022/06/21 06:00 [pubmed] PHST- 2022/06/23 06:00 [medline] PHST- 2022/06/20 00:00 [pmc-release] AID - 10.1186/s12885-022-09783-y [pii] AID - 9783 [pii] AID - 10.1186/s12885-022-09783-y [doi] PST - epublish SO - BMC Cancer. 2022 Jun 20;22(1):676. doi: 10.1186/s12885-022-09783-y.